English

CLINUVEL PHARMACEUTICALS LIMITED

EDGAR

Foreign issuer report (6-K) · filed 2026-10-30

Annual consolidated revenue for 2026: about USD 64.32M, using the latest reported figures. The previous period, 2025, was about USD 61.12M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

64.3 million USD

2026 · USD

Exact inputs and evidence

Revenue: 64315354 USD Source

Operating margin

43.41%

2026 · %

Exact inputs and evidence

Operating Income: 27921593 USD Source
Revenue: 64315354 USD Source

Operating cash flow

12.9 million USD

2026 · USD

Exact inputs and evidence

Operating Cash Flow: 12906429 USD Source

Free cash flow

11.8 million USD

2026 · USD

Exact inputs and evidence

Operating Cash Flow: 12906429 USD Source
Capital Expenditure: 1057747 USD Source

Cash and cash equivalents: 13.9 million USD 2026-06-30 Source
Exact value

13914953 USD
Long-term debt including current maturities: Not available
Shares outstanding: 50.4 million shares 2026-06-30 Source
Exact value

50427898 shares

Reported share-count change

0.61% · 304 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

50123630 shares · 2025-06-30· Source
50427898 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-30.

Financial data available through: 2026-06-30.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2026-06-30
Operating income: 3 of 11 periods available· newest 2026-06-30
Net income: 3 of 11 periods available· newest 2026-06-30
Operating cash flow: 3 of 11 periods available· newest 2026-06-30
Capital expenditure: 3 of 11 periods available· newest 2026-06-30
Total assets: 2 of 11 periods available· newest 2026-06-30
Total liabilities: 2 of 11 periods available· newest 2026-06-30
Current assets: 2 of 11 periods available· newest 2026-06-30
Current liabilities: 2 of 11 periods available· newest 2026-06-30
Cash and cash equivalents: 2 of 11 periods available· newest 2026-06-30
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2026-06-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+5.2%

Prior period

USD 61.12 million

2024-07-01 – 2025-06-30
Current period

USD 64.32 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

64315354 − 61120888 = 3194466 USD

61120888 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
64315354 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CLINUVEL PHARMACEUTICALS LIMITED · 2026-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Year-over-year change in Revenue: 3194466 USD Concept: fundies:Revenue Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 64315354 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2342764 Filing: 000149315226049364 Input fundies:Revenue: 61120888 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2344464 Filing: 000149315226049364
The citation records this snapshot. The page link may show a newer release later.
Net income
+0.2%

Prior period

USD 23.12 million

2024-07-01 – 2025-06-30
Current period

USD 23.18 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

23177834 − 23122864 = 54970 USD

23122864 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
23177834 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CLINUVEL PHARMACEUTICALS LIMITED · 2026-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Year-over-year change in Net income: 54970 USD Concept: fundies:NetIncome Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 23177834 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2397787 Filing: 000149315226049364 Input fundies:NetIncome: 23122864 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2398407 Filing: 000149315226049364
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-52.7%

Prior period

USD 27.3 million

2024-07-01 – 2025-06-30
Current period

USD 12.91 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

12906429 − 27295554 = -14389125 USD

27295554 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
12906429 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CLINUVEL PHARMACEUTICALS LIMITED · 2026-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Year-over-year change in Operating cash flow: -14389125 USD Concept: fundies:OperatingCashFlow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 12906429 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2016929 Filing: 000149315226049364 Input fundies:OperatingCashFlow: 27295554 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2017720 Filing: 000149315226049364
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+455%

Prior period

USD 190,593

2024-07-01 – 2025-06-30
Current period

USD 1.06 million

2025-07-01 – 2026-06-30

Exact inputs and evidence

1057747 − 190593 = 867154 USD

190593 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source
1057747 USD · 2025-07-01 – 2026-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CLINUVEL PHARMACEUTICALS LIMITED · 2026-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Year-over-year change in Capital expenditure: 867154 USD Concept: fundies:CapitalExpenditure Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1057747 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2022407 Filing: 000149315226049364 Input fundies:CapitalExpenditure: 190593 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2023004 Filing: 000149315226049364
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-07-01 – 2026-06-30

Revenue USD 64.32 million 100% of revenue
Cost of revenue USD 10.98 million 17% of revenue
Operating expenses USD 25.41 million 40% of revenue
Operating income USD 27.92 million 43% of revenue
Tax, interest and other Derived USD 4.74 million 7.4% of revenue
Net income USD 23.18 million 36% of revenue

Cash

Operating cash flow USD 12.91 million 20% of revenue
Capital expenditure USD 1.06 million 1.6% of revenue
Free cash flow Derived USD 11.85 million 18% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2024 40%51%
2025 38%57%
2026 36%57%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2024 2023-07-01 – 2024-06-30	57911843	29383503 Derived	28528340	5182166 Derived	23346174	20100002 Derived	Source 2023-07-01 – 2024-06-30: 57911843 USD Inspect Revenue Open source 2023-07-01 – 2024-06-30: 28528340 USD Inspect Operating Income Open source 2023-07-01 – 2024-06-30: 23346174 USD Inspect Net Income Open source 2023-07-01 – 2024-06-30: 23750072 USD Inspect Operating Cash Flow Open source 2023-07-01 – 2024-06-30: 3650070 USD Inspect Capital Expenditure Open source
2025 2024-07-01 – 2025-06-30	61120888	34600831 Derived	26520057	3397193 Derived	23122864	27104961 Derived	Source 2024-07-01 – 2025-06-30: 61120888 USD Inspect Revenue Open source 2024-07-01 – 2025-06-30: 26520057 USD Inspect Operating Income Open source 2024-07-01 – 2025-06-30: 23122864 USD Inspect Net Income Open source 2024-07-01 – 2025-06-30: 27295554 USD Inspect Operating Cash Flow Open source 2024-07-01 – 2025-06-30: 190593 USD Inspect Capital Expenditure Open source
2026 2025-07-01 – 2026-06-30	64315354	36393761 Derived	27921593	4743759 Derived	23177834	11848682 Derived	Source 2025-07-01 – 2026-06-30: 64315354 USD Inspect Revenue Open source 2025-07-01 – 2026-06-30: 27921593 USD Inspect Operating Income Open source 2025-07-01 – 2026-06-30: 23177834 USD Inspect Net Income Open source 2025-07-01 – 2026-06-30: 12906429 USD Inspect Operating Cash Flow Open source 2025-07-01 – 2026-06-30: 1057747 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 64.3M 2026

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-06-30	Revenue	57911843	Revenue: 57911843 Open source
20252025-06-30	Revenue	61120888	Revenue: 61120888 Open source
20262026-06-30	Revenue	64315354	Revenue: 64315354 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

5.2% 2026

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20242024-06-30	Year over year	No prior comparable period	Revenue: 57911843 Open source
20252025-06-30	Year over year	5.5%	Revenue: 61120888 Open source Revenue: 57911843 Open source
20262026-06-30	Year over year	5.2%	Revenue: 64315354 Open source Revenue: 61120888 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 43.4% 2026

Net margin 36% 2026

Free cash flow margin 18.4% 2026

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20242024-06-30	Operating margin	49.3%	Operating Income: 28528340 Open source Revenue: 57911843 Open source
20252025-06-30	Operating margin	43.4%	Operating Income: 26520057 Open source Revenue: 61120888 Open source
20262026-06-30	Operating margin	43.4%	Operating Income: 27921593 Open source Revenue: 64315354 Open source
20242024-06-30	Net margin	40.3%	Net Income: 23346174 Open source Revenue: 57911843 Open source
20252025-06-30	Net margin	37.8%	Net Income: 23122864 Open source Revenue: 61120888 Open source
20262026-06-30	Net margin	36%	Net Income: 23177834 Open source Revenue: 64315354 Open source
20242024-06-30	Free cash flow margin	34.7%	Revenue: 57911843 Open source Operating Cash Flow: 23750072 Open source Capital Expenditure: 3650070 Open source
20252025-06-30	Free cash flow margin	44.3%	Revenue: 61120888 Open source Operating Cash Flow: 27295554 Open source Capital Expenditure: 190593 Open source
20262026-06-30	Free cash flow margin	18.4%	Revenue: 64315354 Open source Operating Cash Flow: 12906429 Open source Capital Expenditure: 1057747 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 12.9M 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-06-30	Operating cash flow	23750072	Operating Cash Flow: 23750072 Open source
20252025-06-30	Operating cash flow	27295554	Operating Cash Flow: 27295554 Open source
20262026-06-30	Operating cash flow	12906429	Operating Cash Flow: 12906429 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 11.8M 2026

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-06-30	Free cash flow	20100002	Operating Cash Flow: 23750072 Open source Capital Expenditure: 3650070 Open source
20252025-06-30	Free cash flow	27104961	Operating Cash Flow: 27295554 Open source Capital Expenditure: 190593 Open source
20262026-06-30	Free cash flow	11848682	Operating Cash Flow: 12906429 Open source Capital Expenditure: 1057747 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

7.5% 2026

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2024-06-30	Liabilities / assets	Not reported	No source recorded
20252025-06-30	Liabilities / assets	11.3%	Total Liabilities: 19997317 Open source Total Assets: 176737951 Open source
20262026-06-30	Liabilities / assets	7.5%	Total Liabilities: 15363451 Open source Total Assets: 203983448 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

14.72× 2026

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2024-06-30	Current assets / current liabilities	Not reported	No source recorded
20252025-06-30	Current assets / current liabilities	9.68×	Current Assets: 170697420 Open source Current Liabilities: 17627532 Open source
20262026-06-30	Current assets / current liabilities	14.72×	Current Assets: 196527135 Open source Current Liabilities: 13352290 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2024 2023-07-01 – 2024-06-30	USD 23.35 million Exact value Exact value: 23346174 USD 2023-07-01 – 2024-06-30: 23346174 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLINUVEL PHARMACEUTICALS LIMITED · 2024-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Net Income: 23346174 USD Concept: fundies:NetIncome Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3ANetIncome&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:NetIncome: 23346174 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2399025 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 23.75 million Exact value Exact value: 23750072 USD 2023-07-01 – 2024-06-30: 23750072 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLINUVEL PHARMACEUTICALS LIMITED · 2024-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Operating Cash Flow: 23750072 USD Concept: fundies:OperatingCashFlow Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3AOperatingCashFlow&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 23750072 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2018509 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 3.65 million Exact value Exact value: 3650070 USD 2023-07-01 – 2024-06-30: 3650070 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CLINUVEL PHARMACEUTICALS LIMITED · 2024-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Capital Expenditure: 3650070 USD Concept: fundies:CapitalExpenditure Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3ACapitalExpenditure&period=2024-06-30&surface=latest&period_type=duration&start=2023-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3650070 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2023597 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 20.1 million Calculation and evidence 23750072 − 3650070 USD Exact free cash flow: 20100002 USD 2023-07-01 – 2024-06-30: 23750072 USD · Inspect Operating Cash Flow · Source 2023-07-01 – 2024-06-30: 3650070 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CLINUVEL PHARMACEUTICALS LIMITED · 2024-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Free cash flow: 20100002 USD Concept: free-cash-flow Period: 2023-07-01 to 2024-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 23750072 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2018509 Filing: 000149315226049364 Input fundies:CapitalExpenditure: 3650070 USD (2023-07-01 to 2024-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2023597 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.
2025 2024-07-01 – 2025-06-30	USD 23.12 million Exact value Exact value: 23122864 USD 2024-07-01 – 2025-06-30: 23122864 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLINUVEL PHARMACEUTICALS LIMITED · 2025-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Net Income: 23122864 USD Concept: fundies:NetIncome Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3ANetIncome&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:NetIncome: 23122864 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2398407 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 27.3 million Exact value Exact value: 27295554 USD 2024-07-01 – 2025-06-30: 27295554 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLINUVEL PHARMACEUTICALS LIMITED · 2025-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Operating Cash Flow: 27295554 USD Concept: fundies:OperatingCashFlow Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3AOperatingCashFlow&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 27295554 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2017720 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 190,593 Exact value Exact value: 190593 USD 2024-07-01 – 2025-06-30: 190593 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CLINUVEL PHARMACEUTICALS LIMITED · 2025-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Capital Expenditure: 190593 USD Concept: fundies:CapitalExpenditure Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3ACapitalExpenditure&period=2025-06-30&surface=latest&period_type=duration&start=2024-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 190593 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2023004 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 27.1 million Calculation and evidence 27295554 − 190593 USD Exact free cash flow: 27104961 USD 2024-07-01 – 2025-06-30: 27295554 USD · Inspect Operating Cash Flow · Source 2024-07-01 – 2025-06-30: 190593 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CLINUVEL PHARMACEUTICALS LIMITED · 2025-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Free cash flow: 27104961 USD Concept: free-cash-flow Period: 2024-07-01 to 2025-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 27295554 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2017720 Filing: 000149315226049364 Input fundies:CapitalExpenditure: 190593 USD (2024-07-01 to 2025-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2023004 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.
2026 2025-07-01 – 2026-06-30	USD 23.18 million Exact value Exact value: 23177834 USD 2025-07-01 – 2026-06-30: 23177834 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLINUVEL PHARMACEUTICALS LIMITED · 2026-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Net Income: 23177834 USD Concept: fundies:NetIncome Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3ANetIncome&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:NetIncome: 23177834 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2397787 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 12.91 million Exact value Exact value: 12906429 USD 2025-07-01 – 2026-06-30: 12906429 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLINUVEL PHARMACEUTICALS LIMITED · 2026-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Operating Cash Flow: 12906429 USD Concept: fundies:OperatingCashFlow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3AOperatingCashFlow&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 12906429 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2016929 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 1.06 million Exact value Exact value: 1057747 USD 2025-07-01 – 2026-06-30: 1057747 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CLINUVEL PHARMACEUTICALS LIMITED · 2026-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Capital Expenditure: 1057747 USD Concept: fundies:CapitalExpenditure Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877/explain?concept=fundies%3ACapitalExpenditure&period=2026-06-30&surface=latest&period_type=duration&start=2025-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1057747 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2022407 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.	USD 11.85 million Calculation and evidence 12906429 − 1057747 USD Exact free cash flow: 11848682 USD 2025-07-01 – 2026-06-30: 12906429 USD · Inspect Operating Cash Flow · Source 2025-07-01 – 2026-06-30: 1057747 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CLINUVEL PHARMACEUTICALS LIMITED · 2026-06-30 CLINUVEL PHARMACEUTICALS LIMITED (edgar:1290877) Free cash flow: 11848682 USD Concept: free-cash-flow Period: 2025-07-01 to 2026-06-30 Values: Latest reported Published: 2026-11-02T20:21:01Z Snapshot: 0a7cf8c874dd3343b2144d809ceb5be3a768c3d8f7f43ce6ead16f870a40e760 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1290877?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 12906429 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2016929 Filing: 000149315226049364 Input fundies:CapitalExpenditure: 1057747 USD (2025-07-01 to 2026-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1290877/000149315226049364/form20-f.htm#2022407 Filing: 000149315226049364 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

15 filings · 160 latest values · 160 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001290877, 1290877, edgar:1290877

Also known as CLINUVEL PHARMACEUTICALS LIMITED, Clinuvel Pharmaceuticals Ltd, EpiTan LTD

CLINUVEL PHARMACEUTICALS LIMITED

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2026 2025-07-01 – 2026-06-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation